Analyzing Cerus Corporation (CERS) and Its Peers
Cerus Corporation (NASDAQ: CERS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Cerus Corporation to similar businesses based on the strength of its valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.
This table compares Cerus Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cerus Corporation Competitors||-101.23%||-92.70%||-30.32%|
This is a summary of current ratings and recommmendations for Cerus Corporation and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cerus Corporation Competitors||109||727||1024||10||2.50|
Cerus Corporation presently has a consensus target price of $7.00, indicating a potential upside of 87.17%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.32%. Given Cerus Corporation’s stronger consensus rating and higher possible upside, analysts plainly believe Cerus Corporation is more favorable than its peers.
Volatility & Risk
Cerus Corporation has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Cerus Corporation’s peers have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.
Insider & Institutional Ownership
58.1% of Cerus Corporation shares are owned by institutional investors. Comparatively, 57.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus Corporation shares are owned by insiders. Comparatively, 9.7% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Cerus Corporation and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cerus Corporation||$39.28 million||-$62.90 million||-6.34|
|Cerus Corporation Competitors||$1.67 billion||$207.58 million||81.53|
Cerus Corporation’s peers have higher revenue and earnings than Cerus Corporation. Cerus Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Cerus Corporation peers beat Cerus Corporation on 7 of the 12 factors compared.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Stock Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related stocks with our FREE daily email newsletter.